TXG * logo

10x Genomics BMV:TXG * Stock Report

Last Price

Mex$440.00

Market Cap

Mex$35.8b

7D

0%

1Y

n/a

Updated

25 Dec, 2024

Data

Company Financials +

10x Genomics, Inc.

BMV:TXG * Stock Report

Market Cap: Mex$35.8b

TXG * Stock Overview

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. More details

TXG * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

10x Genomics, Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.1b

Oxford Nanopore Technologies

LSE:ONT

UK£1.3b

Evotec

XTRA:EVT

€1.5b

Joinn Laboratories(China)Co.Ltd

SHSE:603127

CN¥11.8b

Price History & Performance

Summary of share price highs, lows and changes for 10x Genomics
Historical stock prices
Current Share PriceUS$440.00
52 Week HighUS$440.00
52 Week LowUS$367.32
Beta1.82
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.49%

Recent News & Updates

Recent updates

Shareholder Returns

TXG *MX Life SciencesMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how TXG * performed against the MX Life Sciences industry.

Return vs Market: Insufficient data to determine how TXG * performed against the MX Market.

Price Volatility

Is TXG *'s price volatile compared to industry and market?
TXG * volatility
TXG * Average Weekly Movementn/a
Life Sciences Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: TXG *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine TXG *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20121,259Serge Saxonovwww.10xgenomics.com

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.

10x Genomics, Inc. Fundamentals Summary

How do 10x Genomics's earnings and revenue compare to its market cap?
TXG * fundamental statistics
Market capMex$35.81b
Earnings (TTM)-Mex$3.68b
Revenue (TTM)Mex$12.70b

2.8x

P/S Ratio

-9.7x

P/E Ratio

Is TXG * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TXG * income statement (TTM)
RevenueUS$629.74m
Cost of RevenueUS$210.13m
Gross ProfitUS$419.61m
Other ExpensesUS$602.16m
Earnings-US$182.55m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.51
Gross Margin66.63%
Net Profit Margin-28.99%
Debt/Equity Ratio0%

How did TXG * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:51
End of Day Share Price 2024/09/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

10x Genomics, Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Luke SergottBarclays
Michael RyskinBofA Global Research